Download presentation
1
MYOPIC MACULAR DEGENERATION
CLINICAL ASPECTS and THERAPY ALFREDO PECE
2
RACIAL AND ETHNIC VARIATIONS
68% ESKIMO 75% TAIWAN
3
PREVALENCE OF MYOPIA Age In Taiwan (1995) In western countries
7 years old: 12% 12 years old: 56% 15 years old: 76% 18 years old: 84% In western countries 20 years old: 20%
4
27-33% of the myopic eyes DEGENERATIVE MYOPIA
% of the population 27-33% of the myopic eyes
5
THE PREVALENCE OF MYOPIA INCREASES AS THE LEVEL OF EDUCATION RISES
SOCIOECONOMIC AND ENVIROMENTAL FACTORS THE PREVALENCE OF MYOPIA INCREASES AS THE LEVEL OF EDUCATION RISES GOLDSCHMIDT 1968 STUDENTS 32% FARMWORK,FISHERMEN 2.5% SCHOOLCHILDREN AGED SINGAPORE 37% XIAMEN-CHINA 18.5%
6
P< .0.5 P< .01
7
B. Freund, A. Ciardella, L. Yannuzzi, A. Pece
B.Freund, A.Ciardella, L.Yannuzzi, A.Pece. PERIPAPILLARY DETACHMENT IN PATHOLOGIC MYOPIA. Arch of Ophthalmol, 2003;121:
8
Patologie causa di CNV Oltre 50 anni: AMD Meno di 50 anni miopia 62%
POHS 12% strie angioidi 5% altre 4% idiopatica 17%
9
STAPHYLOMA POSTERIOR POLE MACULAR PERIPAPILLARY NASAL INFERIOR
10
POSTERIOR POLE STAPHYLOMA
44%
11
MACULAR STAFYLOMA 3%
12
13%
13
20% 20%
14
Peripapillary crescent
15
By Centervue
16
CNV FROM THE CRESCENT
17
By OPTOS
18
CHORIORETINAL AREAS OF ATROPHY
19
CHORIORETINAL AREAS OF ATROPHY
21
lacquer cracks
22
Retinography Blu Red-free FAG Red
23
“COIN” LESION
24
1 mo. later natural evolution 2 y later 2 mo.later
25
IN 56% LACQUER CRACKS PROGRESS LACQUER CRACKS & CNV
K.OHNO-MATSUI ET COLL RETINA 16:29-37, 1996. LACQUER CRACKS PROGRESS IN 56% LACQUER CRACKS & CNV
27
CNV CNV AFFECT 5-10% OF THE MYOPIC POPULATION
28
58-74% OF CNV DIRECTLY INVOLVE THE FOVEA ON
INITIAL EXAMINATION CNV
29
Leakage evidente o scarso
CNV a margini ben delimitati CNV a margini mal delimitati
30
Ruolo dell’ ICG
33
Ruolo dell’ ICG= limitato
34
CNV in myopic macular degeneration
35
P.Milani et Al: Importance of SDOCT in Myopic CNV
Courtesy P.Milani B IR AF Initial FA Middle FA Late FA P.Milani et Al: Importance of SDOCT in Myopic CNV
36
OCT IS HELPFUL for the DIAGNOSIS
Myopic CNV often small, mild leakage Myopic Fundus. Staphiloma Multiple areas of chorioretinal atrophy Tassellation-distrophy of the RPE There may be angiographic diagnostic difficulties even when using the SLO which gives more contrast and better definition
37
VISION DISTURBANCES SINCE 2 WEEKS, UNCERTAIN LEAKAGE
CNV PRESENCE ? VISION DISTURBANCES SINCE 2 WEEKS, UNCERTAIN LEAKAGE P. Milani
38
CNV nella PM: diagnosi differenziale
39
CNV nella PM: diagnosi differenziale
40
Storia naturale della CNV nella PM
Perdita visiva 1/2 degli occhi dopo 2 anni 2/3 degli occhi dopo 5-10 anni Involuzione spontanea con buon esito funzionale RARA
41
NATURAL EVOLUTION
42
15 years later
43
New Therapies in MYOPIC-CNV
44
1° DIAGNOSI CORRETTA
45
Myopic CNV
46
2° QUALE TERAPIA?
47
Laser photocoagulation of non-subfoveal myopic CNV
Randomized studies (1,2): effective but VA decreases during the time. No benefit at 5 years Retrospective studies (3): VA decrease 42% (5 years) up to 63% (10 years) in treated vs 68% in untreated NO MORE LASER 1) Soubrane 1986, 2)Fardeau 1992, 3) Secretan 1997
49
4 mo after laser 2 y after laser 4 y after laser
50
VIP Trial: Patients with Pathologic Myopia Primary Visual Acuity Outcome
pdt Eyes with <1.5-line loss (%) 80 P=0.003 Verteporfin-treated patients were more likely to have stabilized vision (defined as losing <1.5 lines) at month 12 60 40 20 Verteporfin (n = 81) Placebo (n = 39)
51
VIP Trial: Patients with Pathologic Myopia
VIP Trial: Patients with Pathologic Myopia. Primary VA Outcome at 2 years Eyes (%) with stable (<1.5 line) and improved (more than 1 line) vision The VIP trial have shown the beneficial effect of PDT in terms of preservation of visual acuity. In fact at 2 years verteporfin-treated patients were more likely to have preserved vision and an higher median visual acuity of 20/64 when compared to 20/100 of untreated group Verteporfin (n = 81) Placebo (n = 39)
53
Background PDT with Verteporfin is currently the only approved treatment for subfoveal CNV that has shown stabilization of vision compared with placebo At 1 year 72% of treated eyes compared with 44% of placebo eyes lost <8 letters (mean visual improvement 0,2 lines at 1 year) At 2 years this treatment benefit was no longer detected (36% vs 51% lost 8 letters) More than 50% persistent leakage at 1 year, 13% visual loss of 3 linee or more at 1 year VIP Trial, Ophthalmol 2001 and 2003
54
EYLEA ® and LUCENTIS ® MACUGEN ® and AVASTIN®
AFLIBERCEPT VEGF RANIBIZUMAB INJECTION AS THE FIRST THERAPY (rhu Fab v1) Fc Avastin (generically known as bevacizumab) and LUCENTIS are both anti-VEGF-A biologics; however, the 2 molecules were developed along parallel yet separate tracks. Although both are derived from a common precursor molecule, an anti-VEGF mouse monoclonal antibody, the rationale and strategies of development of these biologics were independent of one another. In the case of LUCENTIS, the anti-VEGF-A sequences from the precursor mouse monoclonal antibody were introduced into a human Fab framework, generating rhu Fab v1. Using rhu Fab v1 as a starting point, a series of Fabs were created in order to generate optimal VEGF-A binding though an affinity maturation process. The maturation process generated a Fab with a 140-fold higher affinity for VEGF-A than rhu Fab v1 and that is produced in an E. coli expression system. This Fab is now known as LUCENTIS. In contrast, the Avastin group at Genentech inserted the anti-VEGF-A sequences from the precursor mouse monoclonal antibody into a structurally distinct human Fab framework, generating Fab-12. This Fab was later used to create the full-length human IgG now known as Avastin. Avastin did not undergo affinity maturation. Avastin is produced in Chinese hamster ovary (CHO) cells, a different expression system from that used for LUCENTIS. This mammalian expression system is necessary to produce Avastin for 2 main reasons, the first being its large size. E. coli produces large proteins poorly, while CHO cells are fully capable of producing large proteins. The second reason is that mammalian cells can properly glycosylate IgGs like Avastin. Glycosylation is an important factor in conferring stability to full-length IgGs. LUCENTIS is not glycosylated. Thus, LUCENTIS and Avastin were developed for 2 different purposes (neovascular AMD and cancer, respectively) using 2 different development strategies and expression systems. Characterization of the LUCENTIS molecule will be discussed in the next few slides. BEVACIZUMAB PEGAPTANIB
55
RADIANCE (CRFB002F2301) 12 Months Study Results
56
Mean change in BCVA from baseline overtime up to Month 12
Ranibizumab treatment showed a continuous improvement in BCVA in Group I (+13.8 letters) and Group II (+14.4 letters) from baseline to Month 12 In the vPDT group, the BCVA gain was less up to Month 3 and showed a steady increase after switching to ranibizumab treatment Months Mean change (±SE) in BCVA from baseline (ETDRS letters) 13.8 14.4 9.3 D8 12.1 12.5 1.4 Ranibizumab 0.5 mg/vPDT as of Month 3 as per investigators’ discretion ; BCVA: best-corrected visual acuity; D8: Day 8; ETDRS: early treatment diabetic retinopathy study; SE: standard error; VA: visual acuity; vPDT: verteporfin photodynamic therapy
58
W H I C D R U G S H O U L D B E D?
59
Intravitreal bevacizumab in myopic CNV
Prospective interventional case series Mean follow up 12 months - 29 eye (16 pdt,13 naive) Loading phase with 3 monthly IV injections - 3 additional monthly in eyes with recurrent Significant improvement of BCVA (mean of +2.4 lines) - greater improvement in naive eyes (3.7 lines vs 2.0 lines) Significant reduction of central foveal thickness (mean 43 µm, p<0.011) Mean num of i.v. 3.6 (range 3-12) 86% pz required only the loading phase Chan WM, Lay TYY BJO 2009
60
Intravitreal Ranibizumab in myopic CNV
Retrospective interventional case series Maximum follow up 12 months , 16 eyes naive Loading phase with 3 monthly IV injections-3 additional monthly in eyes with recurrent Significant improvement of BCVA (mean 3.0 lines, 75% >2 lines) (Vip study 0,2 lines and 13% visual loss of 3 linee or more at 1 year!!!) Significant reduction of central foveal thickness (from 292 to 233 µm at 6 months)- FAG 93.8% eyes no leakage at 3 months (Vip study leakage in 93.1% at 3 months !!!- More than 50% persistent leakage at 1 year !!! ) Mean num of i.v. 3.8 (range 3-9) 81,3% required only loading phase Lai TY L ,Chan WM, Retina 2009
61
Vadalà M, Pece A, BJO 2011 May;95(5):657-61
Myopic choroidal neovascularization treated with intravitreal Ranibizumab Prospective interventional case series 40 eyes of 39 patients Mean age 53±13 years, mean RE -13.5D Mean follow up 13 months Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study. Vadalà M, Pece A, BJO 2011 May;95(5):657-61
62
Mean num “on demand” intravitreal injection: 2.8
Results Mean baseline VA was 0.67 LogMAR After a follow up of 13 months mean VA improved to 0.27 LOgMAR 82% patients improved VA, 58%>2 lines Mean OCT CRT was reduced from ± 70m at baseline to 175 ± 46 m Mean num “on demand” intravitreal injection: 2.8
63
Intravitreal bevacizumab in myopic CNV
Long-term results of Intravitreal bevacizumab in myopic CNV Prospective interventional case series Follow up 24 months (three montly IVB). 32 eyes and 36 mo for 27 pt Significant improvement of BCVA (from 30 lett to 45 letters ) Mean number of injection was 4.1,1.1,0.5,at one, 2 and 3 years. 47% of pt received only the loading phase Gharbiya M et al, BJO 2012
64
Bevacizumab vs Ranibizumab
25 eyes IVB vs 23 eyes IVR with subfoveal CNV over 18 mos of f-up PRN re-treatment based on detection of fluid on OCT and/or leakage on FA every month Similar results Mean # inj 4.7 with IVB vs 2.5 with IVR over 18 mos f-up Mean VA and CFT Over the Follow-up Iacono P, Parodi MB, Papayannis A, Bandello F. Retina 2012
65
ranibizumab vs bevacizumab in myopic CNV A randomized study Milano
Intravitreal ranibizumab vs bevacizumab in myopic CNV A randomized study Milano Palermo Roma Napoli Messina Pece, M.Vadalà, G.Fasolino, P.Milani, J.Trombetta, G.De Crecchio Graefe’s Arch 2014,
66
multicenter, randomized, prospective case series
Beva vs Ranibizumab multicenter, randomized, prospective case series 78 eyes of 78 patients Mean age 59±13 years, mean RE -13.5D follow up 19 months Mean # inj 2.7 with IVB vs 2.3 with IVR BCVA 54let pre e 54 let post IVB BCVA 45let pre e 58 let post IVR
67
odds ratio 2.96, 95% confidence interval 1.11-7.90, p 0.03
68
4°Messaggio NOVITA’
69
AFLIBERCEPT Fusion protein of key domains from human VEGF
VEGFR1 VEGFR2 1 2 3 4 5 6 7 2 Contains “all human” amino acid sequences Penetrates all layers of the retina (MW ~110,000 Daltons) VEGF Trap-Eye is specially iso-osmotic purified solution formulated for intravitreal injection 3 Fc IgG Fusion protein of key domains from human VEGF receptors 1 and 2 with human IgG Fc 4
70
AFLIBERCEPT: alta affinità di legame con i membri della famiglia VEGF1
Agisce come falso recettore solubile2 1 Blocca e cattura tutte le isoforme del dimero VEGF-A3 2 Blocca l’azione degli altri fattori di accrescimento: PIGF* e VEGF-B3 Lega VEGF-A e PlGF con affinità superiore a quella dei loro recettori naturali2 *PlGF = Fattore di crescita placentare 1. Browning DJ et al. Aflibercept for Age-Related Macular Degeneration: A Game-Changer or Quiet Addition 2. Eylea®, Riassunto delle Caratteristiche di Prodotto. 3. Stewart MW. Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol. 2012;6:
71
Intravitreal AFLIBERCEPT in myopic CNV A prospective study Pece in press
72
Caratteristiche Demografiche
Campione Totale Numero pazienti 32 Femmine, n (%) 28 (88%) Età (media ± SD) 56 ± 13
73
Valori espressi in /10 come media ± SD
Andamento BCVA Refrazione Basale 12 mesi Delta P-value >-15 0.23 ± 0.18 0.41 ± 0.26 0.18 ± 0.13 0.035 Da -15 a -11 0.36 ± 0.32 0.55 ± 0.35 0.18 ± 0.24 0.014 Da -10 a -6 0.40 ± 0.31 0.56 ± 0.30 0.15 ± 0.20 Overall 0.36 ± 0.30 0.53 ± 0.31 0.17 ± 0.21 <0.0001 Valori espressi in /10 come media ± SD
74
Terapia con Aflibercept
Campione Totale Numero iniezioni (media ± SD) range 2.1 ± 1.1 1-4 Durata follow-up 12 mesi
75
Conclusions Intravitreal anti-VEGF drugs appear to be safe and efficacy in eyes with CNV secondary to pathologic myopia. Intravitreal AntiVEGF injections show a significant improvement of functional parameters NO Loading phase How to follow the pt? OCT? FA? VA? Long term controlled clinical trials are warranted to validate these promising results
77
grazie
Similar presentations
© 2025 SlidePlayer.com Inc.
All rights reserved.